Redsense receives patent approval in Sweden for its smart wound care technology for optical measuring of blood and exudate

Redsense Medical announces that the company will receive a patent approval in Sweden for the innovative smart wound care technology that was presented in November, 2018. The patent covers optical sensor measuring and will be valid until 2038.

Redsense has already received substantial interest in the technology from large international wound care companies. The company expects to have a functional prototype ready in Q2, 2019.

“This patent validates that we have created a unique solution that could contribute to improved global wound care. We are aiming to create a strong patent protection for the technology on all important regional markets, while continuing with our product development,” says Redsense Medical’s CEO Patrik Byhmer.

The company’s smart wound care technology makes it possible to develop thin sensor layers for optical measuring of several physiological and biological parameters such as blood and exudate. The layer of sensors can be used separately or integrated directly into smart bandages or adhesive plasters. As the technology enables very cost and resource effective individual wound care, it has potential to revolutionize the global wound care market.

The global market for wound care products

The wound care market was valued at approximately USD 18 billion in 2016, and it is expected to grow at a CAGR of 5.3 % until 2023. The primary drivers of market growth are an ageing global population, a larger number of diabetics and increasing investments in research and development, which is also expected to lead to new research discoveries in this area. Chronic wounds are expected to constitute most of the wound care market up until 2022.

For more information, please contact
Patrik Byhmer, CEO Redsense Medical AB (publ)
Telephone: +46 (0) 35 - 10 60 30
Email: patrik.byhmer@redsensemedical.com
Website: www.redsensemedical.com

About Redsense Medical

Redsense Medical is a corporate group with operations mainly in Europe and the United States. The company has developed the Redsense system, a medical technology product used for monitoring and alarm in the case of blood leakage in connection with hemodialysis. Redsense solves one of the most serious remaining safety problems within hemodialysis – to quickly detect venous needle dislodgement and catheter leakage and minimizing blood leakage. The system consists of a patented fiber optic sensor, designed for either venous needle or central venous catheter, which is connected to an alarm unit. From the very start, the development of the company's technology has been based on the demands and safety requirements of healthcare providers in the dialysis sector.

Redsense Medical AB is listed on Nasdaq First North (ticker: REDS). Certified Adviser: Erik Penser Bank AB, +46 8 4638300, certifiedadviser@penser.se.

Subscribe

Documents & Links